09:28 AM EDT, 10/24/2024 (MT Newswires) -- Arcus Biosciences ( RCUS ) reported "encouraging" first clinical data Thursday from a phase 1/1b study evaluating casdatifan in metastatic clear cell renal cell carcinoma, which is a type of kidney cancer.

The biopharmaceutical company said the trial results showed a rapid time to response with 81% of patients experiencing disease control with either a partial response or stable disease.

Shares of Arcus Biosciences ( RCUS ) were up 6% ahead of the opening bell.

Price: 18.38, Change: +1.05, Percent Change: +6.06